D. E. Shaw & Co., Inc. Castle Biosciences Inc Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 13,382 shares of CSTL stock, worth $291,326. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,382

Previous 52,364 74.44%

Holding current value

$291,326

Previous $1.13 Million 73.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$18.06 - $25.3 $704,014 - $986,244	-38,982 Reduced 74.44%	13,382 $296,000
Q4 2023 Feb 14, 2024	BUY	$12.19 - $22.43 $638,317 - $1.17 Million	52,364 New	52,364 $1.13 Million
Q4 2022 Feb 14, 2023	BUY	$18.08 - $30.0 $25,402 - $42,150	1,405 Added 5.1%	28,937 $681,000
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $619,745 - $944,898	27,532 New	27,532 $718,000
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $277,482 - $480,088	-7,104 Closed	0 $0

Q3 2021 Nov 15, 2021	BUY	$60.13 - $77.6 $427,163 - $551,270	7,104 New	7,104 $472,000
Q2 2021 Aug 16, 2021	SELL	$50.07 - $76.78 $958,990 - $1.47 Million	-19,153 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$58.92 - $97.33 $3,770 - $6,229	64 Added 0.34%	19,153 $1.31 Million
Q4 2020 Feb 16, 2021	BUY	$43.6 - $73.05 $457,451 - $766,440	10,492 Added 122.04%	19,089 $1.28 Million
Q3 2020 Nov 16, 2020	SELL	$38.47 - $52.03 $340,613 - $460,673	-8,854 Reduced 50.74%	8,597 $442,000
Q2 2020 Aug 14, 2020	BUY	$27.28 - $43.01 $476,063 - $750,567	17,451 New	17,451 $658,000

Others Institutions Holding CSTL

# of Institutions

162

Shares Held

25.3M

Call Options Held

82.2K

Put Options Held

150K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $572M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account